Abstract
Age is among the strongest risk factors for severe outcomes from SARS-CoV-2 infection. We sought to evaluate associations between age and both mucosal and systemic host responses to SARS-CoV-2 infection. We profiled the upper respiratory tract (URT) and peripheral blood transcriptomes of 201 participants (age range of 1 week to 83 years), including 137 non-hospitalized individuals with mild SARS-CoV-2 infection and 64 uninfected individuals. Among uninfected children and adolescents, young age was associated with upregulation of innate and adaptive immune pathways within the URT, suggesting that young children are primed to mount robust mucosal immune responses to exogeneous respiratory pathogens. SARS-CoV-2 infection was associated with broad induction of innate and adaptive immune responses within the URT of children and adolescents. Peripheral blood responses among SARS-CoV-2-infected children and adolescents were dominated by interferon pathways, while upregulation of myeloid activation, inflammatory, and coagulation pathways was observed only in adults. Systemic symptoms among SARS-CoV-2-infected subjects were associated with blunted innate and adaptive immune responses in the URT and upregulation of many of these same pathways within peripheral blood. Finally, within individuals, robust URT immune responses were correlated with decreased peripheral immune activation, suggesting that effective immune responses in the URT may promote local viral control and limit systemic immune activation and symptoms. These findings demonstrate that there are differences in immune responses to SARS-CoV-2 across the lifespan, including between young children and adolescents, and suggest that these varied host responses contribute to observed differences in the clinical presentation of SARS-CoV-2 infection by age.
One Sentence Summary Age is associated with distinct upper respiratory and peripheral blood transcriptional responses among children and adults with SARS-CoV-2 infection.
Competing Interest Statement
TWB is a consultant for and owns equity in Biomeme, Inc. KMW held a sponsored research project from Moderna Therapeutics, Inc. on immune correlates of congenital CMV infection. CWW is a consultant for and owns equity in Biomeme, Inc. MSK is a consultant for Merck & Co, Inc. and Invivyd. All other authors declare that they have no competing interests.
Funding Statement
This research was supported by a Merck Investigator Studies Program Grant (MISP #60495) to MSK and through funding provided by the Department of Pediatrics in the Duke University School of Medicine. MSK was supported by a National Institutes of Health Career Development Award (K23-AI135090). JHH was supported by a National Institutes of Health Career Development Award (K01-AI173398). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Duke University Health System Institutional Review Board (Pro00106150). Informed consent was obtained from all study participants or their legal guardians, with written approval obtained using an electronic consent document. The MESSI study was approved by the Duke University Health System Institutional Review Board (Pro00100241). Informed consent was obtained from all study participants, with written approval obtained using an electronic consent document.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data are available in the main text or the supplementary materials. The sequencing dataset supporting the conclusions of this study is available in the Gene Expression Omnibus (accession number: GSE231409). The statistical files and script used for data analyses are also publicly available (https://github.com/mskelly7/COVID_RNASeq_Age).
